ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • educational innovation and fellowship programs
  • Educational innovation and gout
  • educational innovation and health disparities
  • educational innovation and health literacy
  • educational innovation and immunology
  • educational innovation and interdisplinary
  • Educational innovation and juvenile idiopathic arthritis (JIA)
  • educational innovation and knowledge
  • educational innovation and medical student
  • educational innovation and musculoskeletal curriculum
  • Educational innovation and online resources
  • educational innovation and osteoarthritis
  • educational innovation and rheumatic education
  • Educational innovation and rheumatoid arthritis (RA)
  • educational innovation and social media
  • Educational innovation and trainee
  • educational research
  • educational research and educator
  • educational research and epidemiologic methods
  • educational research and ethics
  • educational research and evaluation
  • educational research and health disparities
  • educational research and joint procedures
  • educational research and lupus nephritis
  • educational research and medical education
  • Educational research and motivational interviewing
  • educational research and musculoskeletal curriculum
  • educational research and patient engagement
  • educational research and pediatric rheumatology
  • educational research and pediatrics
  • educational research and primary care
  • educational research and rheumatoid arthritis (RA)
  • educational research and technology
  • educational research and trainee
  • educator
  • educator and fellowship programs
  • educator and grants
  • educator and primary care
  • Effective
  • Effective and race/ethnicity
  • Effective and safety
  • Effective and treatment
  • effective leader and rheumatoid arthritis (RA)
  • Effectiveness
  • efferocytosis and rheumatoid arthritis
  • Efficacy
  • Efficacy and Clinical Response
  • efficacy and drug toxicity
  • Efficacy and safety
  • Efficient
  • Efficient and Electronic Health Record
  • Efficient and management
  • EGFR
  • EGPA
  • Egr1 and tissue growth factor (TGF)
  • eHealth ethics
  • eHealth ethics and rheumatoid arthritis (RA)
  • Ehlers-Danlos
  • Ehlers-Danlos syndrome
  • Ehlers-Danlos syndrome and bone density
  • Ehlers-Danlos syndrome and exercise
  • Ehlers-Danlos syndrome and osteoporosis
  • EHR and diabetes
  • EHR best practices
  • Eicosanoids
  • Elderly
  • Elderly and Angiography
  • Elderly and ankylosing spondylitis (AS)
  • Elderly and antiphospholipid
  • Elderly and disease outcome measures
  • Elderly and fibromyalgia
  • Elderly and Gene Expression
  • Elderly and vasculitis
  • electromyography
  • electromyography and ultrasonography
  • Electronic Health Record
  • Electronic Health Record and consults
  • Electronic Health Record and crystal-induced arthritis
  • Electronic Health Record and health disparities
  • Electronic Health Record and hydroxychloroquine
  • Electronic Health Record and Lupus
  • Electronic Health Record and patient
  • Electronic Health Record and practice improvement
  • Electronic Health Record and prescriptions
  • Electronic Health Record and pseudogout
  • Electronic Health Record and registries
  • Electronic Health Record and rheumatoid arthritis (RA)
  • Electronic Health Record and systemic lupus erythematosus (SLE)
  • Electronic Health Record and systemic sclerosis
  • Electronic Health Record and treatment guidlelines
  • Electronic Health Record and vasculitis
  • electronic health records
  • Elk-1
  • ellis van creveld and cartilage
  • elotuzumab
  • emergency and comorbidity
  • emergency room visits
  • EMG
  • Emmprin
  • Emotions
  • Employment
  • Employment and carpal tunnel syndrome
  • Employment and fibromyalgia
  • Employment and mobile health tool
  • Employment and work
  • Employment and Work Disability
  • Employment status
  • EMR
  • EMRAI and Clinical Characteristics
  • encephalitis and rituximab
  • end-stage renal disease
  • endoplasmic reticulum stress and 4-phenylbutyric acid
  • endothelail cells
  • endothelial
  • endothelial biology
  • endothelial cells
  • endothelial cells and animal models
  • endothelial cells and antiphospholipid antibodies
  • endothelial cells and etanercept
  • endothelial cells and fibrosis
  • endothelial cells and glucocorticoids
  • endothelial cells and inflammatory cytokines
  • endothelial cells and infliximab
  • endothelial cells and interferons
  • endothelial cells and large vessel vasculitis
  • endothelial cells and neutrophils
  • endothelial cells and platelets
  • endothelial cells and renal disease
  • endothelial cells and rheumatoid arthritis
  • endothelial cells and rheumatoid arthritis (RA)
  • endothelial cells and scleroderma
  • endothelial cells and skin
  • endothelial cells and systemic lupus erythematosus (SLE)
  • endothelial cells and systemic sclerosis
  • endothelial cells and takayasu arteritis
  • endothelial cells and vasculitis
  • endothelial progenitor cells
  • enthesis
  • Enthesis and juvenile idiopathic arthritis (JIA)
  • Enthesis and musculoskeletal sonography
  • enthesis and quality of life
  • enthesis and radiography
  • enthesis and spondylarthritis
  • enthesis and T cells
  • Enthesitis
  • Enthesitis and clinical trials
  • Enthesitis and human leukocyte antigens (HLA)
  • Enthesitis and juvenile idiopathic arthritis (JIA)
  • Enthesitis and juvenile spondylarthropathy
  • Enthesitis and psoriatic arthritis
  • Enthesitis and spondylarthritis
  • Enthesitis Related Arthritis
  • Enthesopathy
  • enthesopathy and inflammatory bowel disease (IBD)
  • enthesopathy and phenotypes
  • enthesopathy and quality of life
  • enthesopathy and ultrasonography
  • Enthesopathy and ultrasound
  • Environmental factors
  • environmental factors and epidemiologic methods
  • Environmental factors and familial Mediterranean fever
  • Environmental factors and fibroblasts
  • environmental factors and genetics
  • Environmental factors and gout
  • environmental factors and interferons
  • Environmental factors and juvenile arthritis
  • environmental factors and juvenile dermatomyositis
  • Environmental factors and juvenile idiopathic arthritis (JIA)
  • environmental factors and microparticles
  • environmental factors and myositis
  • environmental factors and prevention
  • environmental factors and registry
  • environmental factors and rheumatoid arthritis (RA)
  • environmental factors and sarcoidosis
  • Environmental factors and systemic lupus erythematosus (SLE)
  • environmental factors and tobacco use
  • environmental pathogens
  • environmental pathogens and differential diagnosis
  • environmental pathogens and epidemiologic methods
  • Enzyme-Linked Immunoabsorbant Assays (ELISA)
  • Enzyme-Linked Immunoabsorbant Assays (ELISA) and antinuclear antibodies (ANA)
  • Enzyme-Linked Immunoabsorbant Assays (ELISA) and heart block
  • Enzyme-Linked Immunoabsorbant Assays (ELISA) and systemic sclerosis
  • eosinophilia
  • Eosinophilic Fasciitis (Shulman's Disease)
  • Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)
  • EPA
  • epicardial adipose tissue
  • epicardial fat
  • Epidemiologic methods
  • epidemiologic methods and Clinical
  • epidemiologic methods and Clinical Response
  • epidemiologic methods and cross-sectional studies
  • epidemiologic methods and exercise
  • epidemiologic methods and extraarticular manifestations
  • epidemiologic methods and fibromyalgia
  • epidemiologic methods and functional status
  • epidemiologic methods and genetics
  • epidemiologic methods and giant cell arteritis
  • Epidemiologic methods and gout
  • First |
  • « Previous Page
  • 15
  • 16
  • 17
  • 18
  • 19
  • [20]
  • 21
  • 22
  • 23
  • 24
  • 25
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology